Ipatasertib

Ipatasertib

Ipatasertib

Chemical compound

Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase II trials for treatment of breast cancer.[1]

Quick Facts Clinical data, Routes ofadministration ...

In vitro, ipatasertib showed activity against all three isoforms of Akt.[2]

References

  1. [1]
    Clinical trial number NCT02301988 for "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer" at ClinicalTrials.gov
  2. [2]
    Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. (April 2013). "Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models". Clinical Cancer Research. 19 (7): 1760–72. doi:10.1158/1078-0432.CCR-12-3072. PMID 23287563.
Share this article:

This article uses material from the Wikipedia article Ipatasertib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.